We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Caterpillar
CAT
$375B
| $61.2M | 0.14% |
342,417
-62,487
| -15% | -$13.2M |
|
152
Public Service Enterprise Group
PEG
$38.2B
| $60.7M | 0.14% |
959,984
-583,000
| -38% | -$39.6M |
|
153
Zoetis
ZTS
$32.4B
| $60.7M | 0.14% |
353,192
-140,832
| -29% | -$24.4M |
|
154
Parker-Hannifin
PH
$123B
| $59M | 0.14% |
239,934
+16,500
| +7% | +$4.42M |
|
|
SBNY
155
DELISTED
Signature Bank
SBNY
| $58.7M | 0.13% |
327,762
+152,107
| +87% | +$34.1M |
|
156
Ametek
AME
$55.4B
| $58.7M | 0.13% |
534,117
-63,511
| -11% | -$7.72M |
|
157
Dollar General
DG
$28B
| $58.5M | 0.13% |
+238,300
| New | +$55.6M |
|
158
Fidelity National Information Services
FIS
$23.1B
| $58.3M | 0.13% |
636,078
+20,200
| +3% | +$2.01M |
|
159
SLB Ltd
SLB
$73.6B
| $58M | 0.13% |
1,620,967
-3,400
| -0.2% | -$142K |
|
160
FedEx
FDX
$72.7B
| $57.4M | 0.13% |
253,304
-1,200
| -0.5% | -$256K |
|
161
Warner Bros
WBD
$65.9B
| $57.4M | 0.13% |
4,278,148
+4,097,829
| +2,273% | +$76M |
|
|
ITCI
162
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $57.3M | 0.13% |
1,003,271
+153,271
| +18% | +$8.69M |
|
163
Emerson Electric
EMR
$83.9B
| $57.2M | 0.13% |
719,236
-957,630
| -57% | -$84.4M |
|
164
Edwards Lifesciences
EW
$49.6B
| $56.8M | 0.13% |
597,566
-54,400
| -8% | -$5.63M |
|
165
Charter Communications
CHTR
$17.3B
| $56.5M | 0.13% |
120,647
-3,800
| -3% | -$1.85M |
|
166
EOG Resources
EOG
$79.2B
| $56.4M | 0.13% |
+510,700
| New | +$63.4M |
|
167
Becton Dickinson
BDX
$45.6B
| $55.9M | 0.13% |
226,915
-16,435
| -7% | -$4.17M |
|
|
NVO
168
Novo Nordisk
NVO
$208B
| $55.6M | 0.13% |
997,610
-120,390
| -11% | -$6.68M |
|
169
Air Products & Chemicals
APD
$65.7B
| $55.5M | 0.13% |
230,940
-50,600
| -18% | -$12.3M |
|
170
Constellation Brands
STZ
$22.2B
| $55.5M | 0.13% |
238,067
+66,500
| +39% | +$16.2M |
|
171
Cenovus Energy
CVE
$55.7B
| $55.1M | 0.13% |
2,900,000
-950,000
| -25% | -$18.9M |
|
172
Incyte
INCY
$24.2B
| $54.8M | 0.13% |
721,109
-871,700
| -55% | -$66.2M |
|
173
Intercontinental Exchange
ICE
$85.6B
| $54.7M | 0.13% |
581,390
-5,300
| -0.9% | -$567K |
|
|
PNTM
174
DELISTED
Pontem Corporation
PNTM
| $53.2M | 0.12% |
5,400,000
| – | – |
|
175
Stryker
SYK
$125B
| $52.8M | 0.12% |
265,499
-100
| -0% | -$23.5K |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.